A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination with Epacadostat in Adults with Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
The study is being done to test any good and bad effects of CRS-207 in combination with epacadostat and pembrolizumab in women with platinum-resistant ovarian, fallopian or peritoneal cancer.
1. Women 18 years or older
2. Platinum-resistant ovarian, fallopian or peritoneal cancer
3. Adequate organ function
4. Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Participants will receive the study drug(s) as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. Participants who stop taking study drug due to reasons other than worsening disease will be contacted and have their disease assessed every 9 weeks until the start of a new anticancer treatment, documented worsening disease or until the end of the study. If a participant stops treatment due to worsening disease, participants will be contacted by phone every 12 weeks after last dose of study drug(s) until the end of the study.
Knight Clinical Trials Information Line
Aduro Biotech, Inc